Jack Schuler Kept Buying QuidelOrtho Below $12 as the Diagnostics Story Was Still Being Rebuilt

Jack Schuler, a 10% owner of QuidelOrtho, bought roughly $2.1M of stock across January 22 to January 26, 2026. That January burst followed earlier 2025 accumulation and stands out because it came while the diagnostics company was still working through a credibility reset rather than celebrating a full turnaround.

What Happened

Date	Insider	Code	Shares	Price	Value
2026-01-26	Jack Schuler	P	20,000	$11.80	$0.24M
2026-01-23	Jack Schuler	P	80,000	$11.81	$0.94M
2026-01-22	Jack Schuler	P	82,465	$10.96	$0.90M
2025-11-24	Joseph Busky	P	4,770	$26.06	$0.12M

Open-market buying is more informative than exercise-related noise, especially in a diagnostics name that had already lost a lot of investor trust. Schuler's purchases signal willingness to add risk while the story still needed proof, not after the easy rerating had already happened.

Why It Matters

The setup matters as much as the dollars. Buyers stepping in below $12 are effectively saying the downside narrative had gone too far. That does not make them automatically right, but it does make the signal stronger than a routine executive option event. This is exactly the distinction covered in our open-market buys versus exercises framework.

QuidelOrtho also sits in a crowded diagnostics landscape next to names like Thermo Fisher, Danaher, Abbott, Illumina, and Quest Diagnostics. That makes insider buying more notable because the buyers had no shortage of alternative places to allocate capital.

What This Is Not

This is not a proof-of-turnaround article. It is an article about incentive alignment and timing. Schuler bought when the market still needed convincing. The read-through is that he saw enough asymmetry to keep adding even before sentiment was repaired.

Key Facts

Primary buyer	Jack Schuler, 10% owner
January 2026 buy value	About $2.1M
Supporting insider context	CFO Joseph Busky had also bought in late 2025
Signal type	Open-market accumulation, not a mechanical option exercise

What to Watch

• QuidelOrtho execution: whether operating progress starts to validate the below-$12 buying window.
• Additional insider activity: whether Schuler keeps buying or the rest of the insider group joins him.
• Peer relative performance: how QuidelOrtho trades versus Thermo Fisher, Danaher, and Abbott.
• Market skepticism: whether the stock still trades as a restructuring story instead of as a recovered diagnostics franchise.
• Ownership structure: whether the 10% owner remains consistently additive in future Form 4 filings.